Vaccination of an immunodominant epitope of myelin basic protein (MBP) (peptide 87–99), shown to be recognized and attacked by the T cell receptor (TCR), prevented and treated EAE, while it reduced tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma production, two determinant cytokines in the pathogenesis of EAE and MS [28]. This evidence concerns the gene MBP and myeloid sarcoma.